Pharmaceutical composition

Details Pharmaceutical composition Pharmaceutical composition

2007-10-31

2011-11-22

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

08063029

ABSTRACT:
A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

REFERENCES:
patent: 3989815 (1976-11-01), Rajadhyaksha
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 3991203 (1976-11-01), Rajadhyaksha
patent: 4122170 (1978-10-01), Rajadhyaksha
patent: 4316893 (1982-02-01), Rajadhyaksha
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4415563 (1983-11-01), Rajadhyaksha
patent: 4423040 (1983-12-01), Rajadhyaksha
patent: 4424210 (1984-01-01), Rajadhyaksha
patent: 4444762 (1984-04-01), Rajadhyaksha
patent: 4992422 (1991-02-01), Minaskanian et al.
patent: 5019395 (1991-05-01), Mahjour et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5855905 (1999-01-01), Oettel et al.
patent: 6190691 (2001-02-01), Mak
patent: 6200602 (2001-03-01), Watts et al.
patent: 6238284 (2001-05-01), Dittgen et al.
patent: 6319913 (2001-11-01), Mak et al.
patent: 6385475 (2002-05-01), Cinquin et al.
patent: 6503894 (2003-01-01), Dudley et al.
patent: 6506572 (2003-01-01), Biedermann et al.
patent: 6723339 (2004-04-01), Meinzer et al.
patent: 6743448 (2004-06-01), Kryger
patent: 7037499 (2006-05-01), Glenn et al.
patent: 7320968 (2008-01-01), Gyurik
patent: 7608605 (2009-10-01), Gyurik
patent: 7608606 (2009-10-01), Gyurik
patent: 7608607 (2009-10-01), Gyurik
patent: 7608608 (2009-10-01), Gyurik
patent: 7608609 (2009-10-01), Gyurik
patent: 7608610 (2009-10-01), Gyurik
patent: 2002/0058650 (2002-05-01), Mak et al.
patent: 2003/0027804 (2003-02-01), van der Hoop
patent: 2008/0103120 (2008-05-01), Gyurik
patent: 2008/0275012 (2008-11-01), Gyurik
patent: 2008/0275013 (2008-11-01), Gyurik
patent: 2009/0192131 (2009-07-01), Gyurik
patent: 2009/0192132 (2009-07-01), Gyurik
patent: WO 02089849 (2002-11-01), None
MerckSource, Dorland's Medical Dictionary-Analgoue, 2007, printed Feb. 17, 2009 from http://www.mercksource.com/pp/us/cns/cns—hl—dorlands—split.jsp?pg=/ppdocs/us/common/dorlands/dorland/one/000004228.htm, 2 pages.
Kenny et al. “Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and Hematocrit in men over age 70 with low testosterone levels”, Endocrine Research, 2000, vol. 26, No. 2, pp. 153-168.
Wang, C., et al., Pharmacokinetics of Transdermal Testerone Gel in Hypgonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study, The Journal of Clinical Endocrinology & Metabolism, 2000, pp. 964-969, vol. 85, No. 3.
Wang C., et al., Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men, The Journal of Clinical Endocrinology & Metabolism, 2000, pp. 2839-53, vol. 85, No. 8.
Cutter, C., Compound Percutaneous Testerone Gel: Use and Effects in Hypogonadal Men, The Journal of American Board Family Practice, Jan.-Feb. 2001, pp. 22-32, vol. 14, No. 1.
Docket for litigation of parent application U.S. Patent No. 7,320,968 (docket retrieved on Mar. 2, 2010).
Complaint for Patent Infringement filed on Dec. 4, 2008 for litigation of parent application U.S. Patent No. 7,320,968.

Affiliated with

Also associated with

Rating

Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4288803